Free delivery on all NHS prescriptions — order now

Wegovy FlexTouch (semaglutide injection)

Images for illustrative purposes only

Wegovy FlexTouch is a once-weekly semaglutide injection for long-term weight management in adults. At Mail My Meds you can buy Wegovy online with a prescription, after an online consultation and BMI check, from £104.99 a month, with discreet, temperature-controlled delivery.

  • Assessed: By a GMC-registered prescriber.
  • Dosing: Once-weekly pre-filled FlexTouch pen.
  • Verified: FitXpress AI body scan BMI check.
  • Delivery: Tracked and temperature-controlled.
In Stock
Discreet Packaging
Prescription included
Quick & Easy
£104.99 
You will need to answer a few questions about your health before completing purchase of this item.

More information

Buy Wegovy online in the UK

You can buy Wegovy online in the UK, but only with a prescription. At Mail My Meds, you complete an online consultation, a UK prescriber reviews it and independently confirms your BMI, and if Wegovy is suitable our GPhC-registered pharmacy dispenses your pen. Prices run from £104.99 a month for the 0.25 mg starting dose to £219.99 a month for the 2.4 mg maintenance dose.

  • Prescription included. Your consultation, prescriber review and prescription are included in the price, with no hidden fees, and you only pay once treatment has been approved.
  • Four weekly doses per pen. Each Wegovy FlexTouch pen covers a month of treatment, and a supply of needles is included.
  • Dispensed by a GPhC-registered pharmacy. Genuine, licensed medicine from a regulated UK pharmacy, prescribed by UK clinicians.
  • BMI checked before prescribing. FitXpress uses two photos to help estimate your measurements, and a prescriber independently verifies your BMI.
  • Discreet, temperature-controlled delivery. Your pen is sent in plain, tracked packaging, and delivery is free on orders over £50.

Wegovy price UK: how much does Wegovy FlexTouch cost?

At Mail My Meds, Wegovy FlexTouch costs from £104.99 a month for the 0.25 mg starting dose to £219.99 a month for the 2.4 mg maintenance dose. The price depends on the strength your prescriber recommends, pricing is fully transparent with no hidden fees, and you only pay once your treatment has been approved by a prescriber.

Wegovy FlexTouch pricing by strength (per month)
Wegovy strengthTypical stage of treatmentPrice per month
0.25 mgStarting (titration) dose£104.99
0.5 mgTitration£124.99
1 mgTitration£129.99
1.7 mgTitration£179.98
2.4 mgMaintenance dose£219.99

Every treatment includes your genuine, licensed medicine, prescriber review, and discreet temperature-controlled delivery. Your prescriber confirms the right dose for you and adjusts it as you move through the titration schedule.

What the first 16 weeks of Wegovy cost

On the standard dose schedule, the four starting strengths cost £539.95 in total over the first 16 weeks, an average of about £135 a month. From week 17, the usual 2.4 mg maintenance dose costs £219.99 a month. Your prescriber may keep you on a lower strength for longer if you have side effects, which changes the total.

Wegovy FlexTouch cost over the standard first 16 weeks
WeeksStrengthPriceRunning total
1 to 40.25 mg£104.99£104.99
5 to 80.5 mg£124.99£229.98
9 to 121 mg£129.99£359.97
13 to 161.7 mg£179.98£539.95
17 onwards2.4 mg£219.99 a monthOngoing

Read more: Wegovy Cost in the UK

How to order Wegovy online at Mail My Meds

Getting started takes just a few minutes online. Because Wegovy is a prescription-only medicine, a prescriber reviews your consultation before any treatment is approved and dispensed, which keeps you safe and makes sure the treatment suits you.

  1. Online consultation. You answer questions about your health, weight history, BMI, medicines and medical conditions. Honest, accurate answers keep you safe.
  2. Clinical review by a prescriber. A UK prescriber checks your answers against the licensed criteria and safety information, and may ask for more detail such as a recent blood pressure reading.
  3. Approval and dispensing. If Wegovy is suitable, your prescription is issued and our pharmacy prepares and dispenses your medicine. If it is not suitable, we explain why and suggest alternatives.
  4. Discreet delivery and support. Your pen arrives in temperature-controlled packaging with the patient information leaflet, and our team supports you throughout treatment.

How FitXpress Supports A Safe Consultation

FitXpress is the Mail My Meds tool that helps you start your consultation and gather what a prescriber needs to assess you, but it supports our clinicians rather than replacing them. A registered prescriber reviews your case, independently confirms your weight, height and BMI, and makes the final decision on whether to prescribe. The steps below show how it works.

How FitXpress works

  1. Start: You tell us which type of treatment you are enquiring about, so we can ask the right questions.
  2. Consult: You complete a confidential medical questionnaire about your health and history.
  3. Scan: You upload two photos (fully clothed, in an A-pose) to help estimate your measurements as part of your assessment.
  4. Clinical review: A GMC-registered prescriber reviews your information, independently verifies your BMI, and issues a prescription only if treatment is appropriate and safe for you.

Top tips for a clear scan:

  • Wear fitted rather than baggy clothing, so your shape is easier to see.
  • Stand in a well-lit area against a plain, light-coloured wall.
  • Use the voice assistant feature if you are taking the photos yourself.
  • Make sure your whole body is visible in the frame.

An Overview From Our Superintendent Pharmacist

At a glance

  • What it is: Wegovy FlexTouch is a pre-filled, multi-dose pen containing semaglutide, a GLP-1 receptor agonist given as a once-weekly injection under the skin.
  • What it is for: long-term weight management in adults living with obesity (BMI of 30 or more), or overweight (BMI of 27 or more) with a weight-related health problem, alongside a reduced-calorie diet and more physical activity.
  • How it works: semaglutide mimics a natural gut hormone that acts on appetite centres in the brain, helping you feel fuller for longer and eat less.
  • Cardiovascular use: semaglutide 2.4 mg is also licensed to reduce the risk of major adverse cardiovascular events in adults with established heart disease and overweight or obesity.
  • How you get it: you complete an online consultation, and a prescriber decides whether Wegovy is right for you before it is dispensed.
  • Main side effects: mostly gastrointestinal, such as nausea, diarrhoea, constipation and vomiting, which often ease as your body adjusts.

"Semaglutide has changed how we support people living with obesity, but it is a long-term medical treatment, not a quick fix or a cosmetic product. It works best when it sits alongside changes to diet, activity and sleep, and it needs proper clinical oversight because it is not right for everyone. If weight has affected your health and lifestyle changes alone have not been enough, the safest first step is a consultation so a prescriber can check your history, your BMI and your goals, and talk you through whether treatment is appropriate for you."

Rachael Clarke MRCPharm, Superintendent Pharmacist

Why choose Mail My Meds for your weight-loss treatment?

Mail My Meds is a GPhC-registered UK online pharmacy, so your Wegovy treatment is prescribed by UK clinicians and dispensed by a regulated pharmacy, not bought from an unregulated seller. Here is what you get when you start your weight-management journey with us.

  • Regulated and safe. A GPhC-registered pharmacy with UK-based prescribers and pharmacists, dispensing genuine, licensed medicine.
  • A simple online consultation. A short, confidential health questionnaire, reviewed by a clinician who decides whether treatment is appropriate for you.
  • Discreet, temperature-controlled delivery. Your pen arrives in plain, tracked packaging using cold-chain delivery that keeps the medicine at the right temperature.
  • Ongoing clinical support. We support you through every dose increase, with regular reviews and pharmacist advice whenever you need it.
  • Transparent pricing. Clear prices with no hidden fees, and you only pay once treatment has been approved.

What is Wegovy FlexTouch, and how does semaglutide work?

Wegovy FlexTouch is a brand of semaglutide, a medicine known as a GLP-1 receptor agonist, delivered by a pre-filled injection pen once a week. Semaglutide copies the action of glucagon-like peptide-1 (GLP-1), a hormone your gut releases after eating that tells your brain you are full.

By activating GLP-1 receptors in the appetite-regulating areas of the brain, including the hypothalamus, semaglutide increases feelings of satiety and reduces hunger and food cravings. It also slows the rate at which the stomach empties, so you feel satisfied for longer after a meal. Together, these effects help most people eat less, which creates the calorie deficit needed for weight loss.1 These appetite effects are well described in the research: in a study of semaglutide's effects on appetite and energy intake published in Diabetes, Obesity and Metabolism, participants ate less and reported improved control of eating.2

Semaglutide also helps regulate blood sugar, which is why a related medicine (Ozempic) is used in type 2 diabetes. Wegovy is the brand licensed specifically for weight management and cardiovascular risk reduction, not for diabetes.

Read more: How Does Wegovy Work?

How does the FlexTouch pen work, and what is the dosing schedule?

The Wegovy FlexTouch pen is a pre-filled, multi-dose device that you inject under the skin once a week, on the same day each week, at any time of day, with or without food. Treatment follows a fixed dose-escalation (titration) schedule that starts low and increases gradually to reduce side effects.

You inject into the abdomen (tummy), thigh or upper arm, rotating the site each week.1 The pen is designed for use with NovoFine Plus, NovoFine or NovoTwist needles, and a supply of needles is included. It must never be given into a vein or muscle.

Standard Wegovy dose-escalation schedule (adults)
WeeksWeekly dosePurpose
Weeks 1 to 40.25 mgStarting dose to let your body adjust
Weeks 5 to 80.5 mgFirst increase
Weeks 9 to 121 mgSecond increase
Weeks 13 to 161.7 mgThird increase
Week 17 onwards2.4 mgUsual maintenance dose

The 0.25 mg starting dose is not a treatment dose. It exists to reduce gastrointestinal side effects such as nausea. Your prescriber usually moves you up every 4 weeks, but may hold you at a lower dose for longer if side effects are troublesome.1 The Summary of Product Characteristics notes that, for some people, the dose may be increased further after at least four weeks on 2.4 mg. Your prescriber will advise on the right dose for you.

Storage made simple: Wegovy is easy to store and does not need to stay in the fridge the whole time. Keep unopened pens in a refrigerator at 2°C to 8°C until you are ready to start. Once you begin using a pen, it does not need continuous refrigeration and can be kept at room temperature, below 30°C, for up to 6 weeks, so it is easy to keep at home or take with you. Never freeze Wegovy, and keep the cap on to protect it from light.3

Read more: How to Use the Wegovy Pen (FlexTouch) · Wegovy Dosage: The Dose Schedule Explained · Wegovy Injection Sites: Where to Inject

How common is obesity in the UK, and what causes it?

Obesity is very common in the UK. Around 30% of adults in England are living with obesity, and a further 36% are overweight, meaning roughly two in three adults are above a healthy weight.4 It is now recognised as a chronic, relapsing medical condition, not simply a matter of willpower.

Being overweight or obese usually results from a long-term imbalance between the calories you take in and the calories you use, but many factors feed into that balance. As the UK government's Foresight report set out, obesity develops from a complex interaction of biological, behavioural, social and environmental factors rather than one single cause.5 Common contributors include:

  • Diet and environment: easy access to energy-dense, highly processed foods and large portion sizes.
  • Physical inactivity: sedentary work, screen time and limited daily movement.
  • Genetics and family history: genes influence appetite, metabolism and where you store fat.
  • Sleep and stress: poor sleep and chronic stress affect the hormones that control hunger.
  • Some medical conditions and medicines: for example an underactive thyroid, polycystic ovary syndrome (PCOS), Cushing's syndrome, and certain steroids, antidepressants or antipsychotics.
  • Social and economic factors: cost, time and access can all shape day-to-day choices.

Carrying excess weight raises the risk of type 2 diabetes, heart disease, stroke, several cancers, joint problems and obstructive sleep apnoea, which is why the NHS treats weight as an important health issue rather than an appearance one.6 Getting the right clinical support, rather than going it alone, can make a real difference, and our prescribers assess your health and help you find a treatment plan that suits you.

Who is Wegovy FlexTouch suitable for?

Wegovy is licensed for adults with an initial body mass index (BMI) of 30 kg/m² or more (obesity), or 27 kg/m² to under 30 kg/m² (overweight) when at least one weight-related health problem is present, such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. It is always used alongside a reduced-calorie diet and increased physical activity.1 Its weight-management licence is supported by the STEP clinical trial programme, including the pivotal STEP 1 trial.7

Separately, semaglutide 2.4 mg is also licensed to reduce the risk of major adverse cardiovascular events (heart attack, stroke or cardiovascular death) in adults with established cardiovascular disease and either obesity or overweight (BMI of 27 or more). The MHRA approved this cardiovascular use in 2024, and in 2026 NICE recommended it for eligible patients, reflecting the results of the large SELECT cardiovascular outcomes trial.8,9 Further trials, such as the STEP-HFpEF trial, have shown benefits for people who have obesity alongside heart failure with preserved ejection fraction.10

On the NHS, access is narrower. NICE (technology appraisal TA875) recommends semaglutide for weight management only within a specialist weight management service, generally for people with a BMI of at least 35 (or 32.5 for some ethnic backgrounds) plus a weight-related condition, for a maximum of two years.11 Through a private online consultation, eligibility is assessed against the licensed criteria above, and a prescriber confirms it is clinically appropriate and safe for you.

Read more: Who Can Take Wegovy?

"BMI is only the starting point. Before approving treatment we look at the whole picture, including your medical history, any other medicines you take, previous experiences with weight loss, and whether there is an underlying cause that needs addressing first. That is why a genuine clinical assessment matters far more than simply meeting a number."

Rachael Clarke MRCPharm, Superintendent Pharmacist

How do weight-loss treatments compare?

Weight-loss treatments range from lifestyle and behavioural support, through pharmacy and prescription medicines, to weight-loss (bariatric) surgery. The right option depends on your BMI, your health, how much weight you need to lose and what you have already tried. GLP-1 based prescription medicines, taken alongside diet and activity, are now among the most widely used medical treatments.

Common approaches to weight management compared
ApproachHow it worksTypical useGood to know
Diet, activity and behavioural supportCreates a calorie deficit and builds lasting habitsFirst-line for everyone, and the foundation for any medicineFree NHS and community options exist; results vary and can be hard to sustain alone
Orlistat (for example Alli, Xenical)Blocks absorption of some dietary fat in the gutPharmacy medicine (orlistat 60 mg) or prescription (120 mg)Non-GLP-1; can cause oily, urgent stools if your diet is high in fat
GLP-1 receptor agonist (semaglutide, e.g. Wegovy)Reduces appetite and slows stomach emptyingPrescription-only, once-weekly injection, gated behind a consultationUsed with diet and activity; some versions also lower cardiovascular risk
Dual GIP/GLP-1 agonist (tirzepatide, as in Mounjaro)Acts on two gut-hormone receptors that regulate appetitePrescription-only, once-weekly injectionA newer option assessed during your consultation if appropriate
Weight-loss (bariatric) surgeryReduces stomach size or alters digestionNHS or private, usually for higher BMIsMost effective for severe obesity; involves surgery and lifelong follow-up

Semaglutide is also available as a once-daily tablet, the Wegovy pill (oral semaglutide).

Prescription weight-loss injections have become popular because, for many people, they make appetite easier to control than diet and willpower alone. They are not magic, though. Weight tends to return if treatment stops without lasting lifestyle change, so they are best seen as one part of a long-term plan rather than a standalone cure. Your prescriber will help you weigh up the options.

The evidence base behind these options is substantial. Semaglutide's weight-management licence rests on the STEP 1 trial, the SURMOUNT-1 trial supports tirzepatide, and the head-to-head SURMOUNT-5 trial compared the two directly. A 2025 systematic review and meta-analysis in Nature Medicine weighed up the comparative benefits and risks of anti-obesity medicines, the XENDOS study remains a landmark trial for orlistat, and the Swedish Obese Subjects study provides long-term outcomes for weight-loss surgery.7,12,13,14,15,16

Read more: Wegovy vs Mounjaro · Wegovy Pill vs Wegovy Injection · Wegovy vs Ozempic · Wegovy vs Saxenda

What are the common side effects of Wegovy FlexTouch?

The most common side effects of Wegovy are gastrointestinal, especially nausea, diarrhoea, vomiting and constipation. They are usually mild to moderate, tend to appear when the dose is increased, and often settle as your body gets used to the medicine.1

Side effects by how often they are reported
How commonExamples
Very common (more than 1 in 10 people)Nausea, diarrhoea, constipation, vomiting, headache, tiredness
Common (up to 1 in 10 people)Indigestion, burping, bloating, stomach pain, dizziness, gallstones, injection-site reactions, hair loss
Less common but seriousInflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar, allergic reactions

Nausea is the side effect people notice most, particularly in the early weeks. Eating smaller, lower-fat meals, stopping when you feel full and staying hydrated can help. Because vomiting and diarrhoea can cause dehydration, which in rare cases can affect the kidneys, it is important to drink enough fluids.1 Independent research has helped quantify these risks: a 2023 study in JAMA examined gastrointestinal adverse events with GLP-1 medicines used for weight loss, and a 2022 meta-analysis in JAMA Internal Medicine assessed the risk of gallbladder and biliary disease.17,18 Always read the patient information leaflet supplied with your pen for the full list of side effects.

Read more: Wegovy Side Effects and How to Manage Them

"Most side effects are the digestive kind and they usually improve with time and slow dose increases. The symptoms I never want people to ignore are severe, persistent tummy pain that may spread to the back, which can signal pancreatitis, or signs of gallbladder trouble. If that happens, stop and seek urgent medical advice rather than pushing on."

Rachael Clarke MRCPharm, Superintendent Pharmacist

What are the warnings and precautions?

Wegovy is a prescription-only medicine because it is not safe or suitable for everyone, and it needs clinical oversight. You should not use it if you are allergic to semaglutide, and it is not recommended in pregnancy or while breastfeeding.3

Tell the prescriber about your full medical history during your consultation. Extra care or closer monitoring is needed if you have or have had:

  • Pancreatitis, gallstones or gallbladder disease. GLP-1 medicines can raise the risk of both.17,18
  • Type 2 diabetes treated with insulin or a sulfonylurea. The combination can cause low blood sugar (hypoglycaemia), so doses may need adjusting.
  • Severe kidney, liver, heart or digestive conditions, including diabetic eye disease (retinopathy).
  • A personal or family history of medullary thyroid cancer or MEN 2. Discuss this with the prescriber, as it is a recognised precaution for this class of medicine.

If you are planning a pregnancy, the guidance is to stop semaglutide at least two months beforehand.3 Never share your pen or use a medicine prescribed for someone else, and never buy semaglutide from unregulated sellers or social media, where fake and unsafe products are a real risk.

When should you see a doctor?

Seek urgent medical help if you have severe or ongoing stomach pain, especially pain that spreads to your back with or without vomiting, as this can be a sign of pancreatitis. Also get prompt advice for signs of a serious allergic reaction, gallbladder problems or symptoms of low blood sugar.

Contact a doctor, pharmacist or call NHS 111 if you experience:

  • Persistent vomiting or diarrhoea, or signs of dehydration such as feeling very thirsty, dizzy or passing little urine.
  • Yellowing of the skin or eyes, pain in the upper-right abdomen, or fever, which can indicate gallbladder or liver problems.
  • Shakiness, sweating, confusion or a fast heartbeat, which can be signs of hypoglycaemia (more likely if you also take diabetes medicines).
  • A rash, swelling of the face, lips or throat, or difficulty breathing. Call 999 for severe allergic reactions.

What can you expect from Wegovy treatment?

Most people on GLP-1 treatment describe a noticeable drop in appetite and in the constant thinking about food, along with feeling full sooner during meals. Weight change tends to be gradual rather than sudden, and it works best alongside changes to your diet and activity. Experiences vary from person to person, and results are not guaranteed.

Common themes people report include:

  • Early side effects: nausea or an unsettled stomach in the first few weeks or after a dose increase, which usually eases.
  • Gradual, steady change: weight loss tends to be progressive over months, and works best with diet and activity changes.
  • Plateaus: weight loss often slows over time, which is normal and worth discussing at a review rather than stopping abruptly.
  • The emotional side: relief and improved confidence for some, and frustration for others when progress is slower than hoped. Support helps.

These patterns are reflected in the research. The STEP 1 trial extension found that weight tends to return once semaglutide is stopped, while the two-year STEP 5 trial and the STEP 4 maintenance trial show that continued treatment helps sustain weight loss. A 2026 systematic review mapped how weight is regained after GLP-1 treatment ends.19,20,21,22 That is why our clinicians keep reviewing your progress and adjusting your plan.

Read more: How Long Does Wegovy Take to Work? · What Happens When You Stop Wegovy?

Can you manage your weight without medication?

Yes. For many people, changes to diet, physical activity, sleep and behaviour are enough to reach and maintain a healthier weight, and these changes remain essential even if you do take medication. Lifestyle support is the foundation of every weight-management plan.

  • Balanced, reduced-calorie eating: plenty of vegetables, fibre and protein, with fewer sugary and highly processed foods. A modest daily calorie reduction is more sustainable than crash dieting.
  • Regular physical activity: the NHS recommends at least 150 minutes of moderate activity a week, plus strength work on two days.
  • Better sleep and stress management: both influence appetite hormones and food choices.
  • Behavioural and peer support: the free NHS Digital Weight Management Programme, local tier 2 services, and structured programmes can improve results.
  • Reducing alcohol: alcoholic drinks add calories that are easy to overlook.

Structured lifestyle programmes are backed by strong evidence. The UK DiRECT trial showed that an intensive, diet-led programme delivered in primary care can produce substantial weight loss and put type 2 diabetes into remission, and the Look AHEAD study examined the long-term effects of intensive lifestyle intervention.23,24

If you have tried these steps and your weight is still affecting your health, that is a good moment to talk to a clinician about whether medical treatment could help.

Frequently Asked Questions

Can you buy Wegovy online in the UK?

Yes, but only with a prescription. Wegovy is a prescription-only medicine, so an online pharmacy can supply it only after a prescriber has reviewed your consultation and confirmed it is suitable. At Mail My Meds, a UK prescriber reviews your answers and independently verifies your BMI before our GPhC-registered pharmacy dispenses your pen.

Is it safe to buy Wegovy online?

Yes, when you use a UK-registered pharmacy that assesses your health and checks your BMI before prescribing. You can check any online pharmacy on the General Pharmaceutical Council register. Websites that offer Wegovy without a prescription or consultation are operating illegally and may supply fake or unlicensed products.

What is included in the price of Wegovy?

At Mail My Meds, the price includes your consultation, prescriber review and prescription, the Wegovy FlexTouch pen with needles, and discreet temperature-controlled delivery. There are no hidden fees, and you only pay once treatment has been approved.

Is Wegovy FlexTouch available without a prescription?

No. Wegovy is a prescription-only medicine (POM), so it cannot be sold over the counter. It can only be supplied after a prescriber has reviewed your online consultation and agreed it is clinically appropriate for you.

How much does Wegovy FlexTouch cost at Mail My Meds?

Wegovy FlexTouch costs from £104.99 a month for the 0.25 mg starting dose to £219.99 a month for the 2.4 mg maintenance dose, depending on the strength your prescriber recommends. Pricing is transparent with no hidden fees, the price includes your medicine and discreet temperature-controlled delivery, and you only pay once treatment has been approved.

How much weight can you lose on Wegovy?

Results vary from person to person, and weight loss is not guaranteed. In clinical trials, semaglutide 2.4 mg led to clinically meaningful, sustained weight loss when combined with a reduced-calorie diet and increased physical activity. Your prescriber can discuss realistic expectations based on your health and circumstances.

How is Wegovy FlexTouch delivered, and is it discreet?

Your Wegovy pen is dispensed by our GPhC-registered pharmacy and sent in plain, discreet packaging using tracked, temperature-controlled (cold-chain) delivery that keeps the medicine at the right temperature. You will be able to choose a convenient delivery option once your treatment is approved.

How is Wegovy FlexTouch injected?

You inject it under the skin (subcutaneously) once a week using the pre-filled FlexTouch pen, into the abdomen, thigh or upper arm. You can inject at any time of day, with or without food, and it helps to rotate the injection site each week. Your consultation includes guidance on using the pen safely.

Why does Wegovy need to start at a low dose?

The 0.25 mg starting dose reduces gastrointestinal side effects such as nausea while your body adjusts. The dose is then increased in steps, usually every four weeks, up to the 2.4 mg maintenance dose. This gradual titration is a standard part of treatment.

Does Wegovy have benefits beyond weight loss?

Yes. As well as weight management, semaglutide 2.4 mg is licensed to reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in adults with established cardiovascular disease and overweight or obesity. This followed the SELECT trial and was approved by the MHRA and recommended by NICE.

How should Wegovy FlexTouch be stored?

Wegovy is easy to store and does not need to stay in the fridge the whole time. Keep unopened pens in a refrigerator at 2°C to 8°C until you are ready to start. Once you begin using a pen, it does not need continuous refrigeration and can be kept at room temperature, below 30°C, for up to six weeks. Never freeze Wegovy, and keep the cap on to protect it from light.

What happens if you miss a weekly dose?

If it has been five days or less since your missed dose, take it as soon as you remember. If more than five days have passed, skip it and take your next dose on your usual scheduled day. Never take two doses close together. If you are unsure, ask your pharmacist.

Will I get support during treatment?

Yes. Our clinical team supports you throughout treatment, from your first consultation through each dose increase and regular reviews. If you have side effects or questions, our pharmacists and prescribers are here to help, and we check your progress before issuing repeat treatment.

Can you get Wegovy on the NHS?

Sometimes. NICE recommends semaglutide for weight management only within a specialist weight management service, generally for people with a BMI of at least 35 plus a weight-related condition, for up to two years. Availability and waiting times vary. A private online consultation assesses eligibility against the licensed criteria.

Wegovy guides

Medical disclaimer

This information is provided for general informational and educational purposes only. It is not medical advice and should not replace a consultation with a qualified healthcare professional who knows your individual circumstances. Always read the patient information leaflet supplied with your medicine, and speak to your prescriber, pharmacist or GP before starting, stopping or changing any treatment. If you think you are experiencing a medical emergency, call 999 or go to your nearest A and E.

Our commitment to content accuracy

Our health content is written and checked with care, and reviewed regularly by our team of pharmacists and clinicians to keep it accurate, evidence-based and up to date. We use trusted sources such as the NHS, NICE, the British National Formulary (BNF), the MHRA and the manufacturer's Summary of Product Characteristics. If you spot something that needs updating, please let us know so we can put it right.

Sources and references

Key studies, trials and reviews

  1. Novo Nordisk. Wegovy 2.4 mg FlexTouch, Summary of Product Characteristics (SmPC). electronic medicines compendium (emc). Accessed August 2026.
  2. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 2017.
  3. Novo Nordisk. Wegovy 2.4 mg FlexTouch, Patient Information Leaflet (PIL). electronic medicines compendium (emc). Accessed August 2026.
  4. House of Commons Library. Obesity statistics (drawing on the Health Survey for England, NHS England Digital), 2026.
  5. Butland B, et al. Tackling Obesities: Future Choices (Foresight report). UK Government Office for Science, 2007.
  6. NHS. Obesity: overview, causes and health risks. Accessed August 2026.
  7. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
  8. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA approves semaglutide to reduce the risk of cardiovascular events, 2024.
  9. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine, 2023.
  10. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine, 2023.
  11. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity (TA875), 2023.
  12. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  13. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025.
  14. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature Medicine, 2025.
  15. Torgerson JS, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care, 2004.
  16. Sjostrom L, et al. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects (SOS). New England Journal of Medicine, 2007.
  17. Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With GLP-1 Receptor Agonists for Weight Loss. JAMA, 2023.
  18. He L, et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis. JAMA Internal Medicine, 2022.
  19. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
  20. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021.
  21. Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022.
  22. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, 2026.
  23. Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet, 2018.
  24. The Look AHEAD Research Group. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes (Look AHEAD). New England Journal of Medicine, 2013.

Further reading

Author

Content author

Dayna Sheppard

Pharmacy Manager and Accuracy Checking Dispenser

Dayna manages the pharmacy team. She has over 15 years of pharmacy experience, over four of them at Mail My Meds.

Read more

Medically Reviewed By:

Medically Reviewed By:

Taslima Hussain

Pharmacist

Taslima is a pharmacist from Newcastle. She graduated with a Master of Pharmacy (MPharm) from Newcastle University in 2022 and worked mainly in community pharmacy as a locum before joining Mail My Meds full time.

Read more

Your trusted NHS pharmacy delivering prescriptions across the UK.

Superintendent Pharmacist:

Rachael Clarke

MRCPharm MFRPSI FRSPH

GPhC Reg: 2061366

Premises GPhC Reg: 9011560

Our Prescriber:

Dr Seth Rankin

GMC Registration Number: 4467397

London Medical Laboratory Ltd

CQC Registration Number: 1-21677335073

Prescriptions are issued by London Medical Laboratory Ltd, registered with the Care Quality Commission.

Contact Us

Location

Unit 1, Karmjit House,
Balliol Business Park,
Newcastle upon Tyne NE12 8EW

9am - 5pm

Mon - Fri

Information Commissioner's OfficeProviding NHS servicesVerify LegitScript Approval for www.mailmymeds.co.uk
Pay securely with
card_visa
card_mastercard
card_amex
card_apple
card_google

Mail My Meds
© 2026 MailMyMeds Pharmacy